Unlike the current clinically available c-MET inhibitors and c-MET mAbs, which exert anti-tumour activity by inhibiting c-MET signal transduction, the new c-MET ADC SHR-A1403 exerts anti-tumour activity through the intracellular release of SHR152852. Here, MET is linked to neoplasm.